Bcr-Abl Kinase Domain Mutations and the Unsettled Problem of Bcr-AblT315I: Looking into the Future of Controlling Drug Resistance in Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Bcr-Abl Kinase Domain Mutations and the Unsettled Problem of Bcr-AblT315I: Looking into the Future of Controlling Drug Resistance in Chronic Myeloid Leukemia

Published:2007-03 Issue: Volume:7 Page:S120-S130
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

O'Hare Thomas,Eide Christopher A.,Deininger Michael W.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference61 articles.

1. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment;Cowan-Jacob;Mini Rev Med Chem,2004

2. Dodging the magic bullet: understanding imatinib resistance;Daley;Cancer Biol Ther,2003

3. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib;Kobayashi;N Engl J Med,2005

4. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient;Tamborini;Gastroenterology,2004

5. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products;Lugo;Science,1990

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating amino acids into Bcr-Abl inhibitors: design, synthesis, biological evaluation, and in silico studies;RSC Medicinal Chemistry;2024

2. Design, synthesis and antitumor evaluation of 3‑chloro-4 - (pyridin-2-ylmethoxy) aniline derivatives as BCR-ABL kinase;Journal of Molecular Structure;2023-06

3. Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors;European Journal of Medicinal Chemistry;2022-08

4. Design, synthesis, and biological evaluation of novel Bcr-AblT315I inhibitors incorporating amino acids as flexible linker;Bioorganic & Medicinal Chemistry;2021-10

5. Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase;Angewandte Chemie International Edition;2021-08-11